Vitestro Raises $70 Million to Advance Autonomous Blood Collection Robot

March 12, 2026
Vitestro has closed a $70 million Series B funding round to support development and commercialization of its Aletta Autonomous Robotic Phlebotomy Device, with participation from Labcorp Venture Fund, Mayo Clinic, and Sutter Health.

Dutch medical robotics company Vitestro has raised $70 million in an oversubscribed Series B round to advance its autonomous robotic blood collection system, announced in a press release. The funding includes new strategic investments from Labcorp Venture Fund, Mayo Clinic, and Sutter Health, alongside financial investors such as InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht.

The proceeds will be used to further develop the next-generation Aletta Autonomous Robotic Phlebotomy Device (ARPD), expand clinical and manufacturing operations, and prepare for global commercialization. Vitestro also plans to pursue U.S. FDA De Novo regulatory clearance as it progresses from European market entry toward the U.S.

Aletta uses multimodal imaging, robotics, and artificial intelligence to identify veins, guide needle insertion, and collect samples autonomously. The device is designed to standardize blood collection quality, support clinical workflows, and reduce staffing pressures in high-volume outpatient settings.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Robotics Brief, Life AI Weekly or Daily AI Brief.

Subscribe to Robotics Brief

Weekly coverage of AI-driven robotics advances in industrial automation, autonomous vehicles, and robotic systems.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more